The Europe Pharmaceutical CDMO market size is evaluated at USD 45.68 billion in 2025 and is forecasted to hit around USD 88.84 billion by 2034, growing at a CAGR of 7.62% from 2025 to 2034. The Germany market size was accounted at USD 12.68 billion in 2024 and is expanding at a CAGR of 7.32% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Europe Pharmaceutical CDMO Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Europe Pharmaceutical CDMO Market Revenue and Volume, By Product
8.1.1 Active Pharmaceutical Ingredient (API) Manufacturing
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Finished Dosage Formulation (FDF) Development & Manufacturing
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Secondary Packaging
8.1.3.1. Market Revenue and Volume Forecast
9.1. Europe Pharmaceutical CDMO Market Revenue and Volume, By Research Phase
9.1.1. Pre-clinical
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Phase I
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Phase II
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Phase III
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Phase IV
9.1.5.1. Market Revenue and Volume Forecast
10.1. Europe
10.1.1. Market Revenue and Volume Forecast, By Product
10.1.2. Market Revenue and Volume Forecast, By Research Phase
10.1.2. Germany
10.1.2.1. Market Revenue and Volume Forecast, By Product
10.1.2.2. Market Revenue and Volume Forecast, By Research Phase
10.1.3. UK
10.1.3.1. Market Revenue and Volume Forecast, By Product
10.1.3.2. Market Revenue and Volume Forecast, By Research Phase
10.1.4. France
10.1.4.1. Market Revenue and Volume Forecast, By Product
10.1.4.2. Market Revenue and Volume Forecast, By Research Phase
10.1.5. Italy
10.1.5.1. Market Revenue and Volume Forecast, By Product
10.1.5.2. Market Revenue and Volume Forecast, By Research Phase
10.1.6. Spain
10.1.6.1. Market Revenue and Volume Forecast, By Product
10.1.6.2. Market Revenue and Volume Forecast, By Research Phase
10.1.7. Sweden
10.1.7.1. Market Revenue and Volume Forecast, By Product
10.1.7.2. Market Revenue and Volume Forecast, By Research Phase
10.1.8. Denmark
10.1.8.1. Market Revenue and Volume Forecast, By Product
10.1.8.2. Market Revenue and Volume Forecast, By Research Phase
10.1.9. Norway
10.1.9.1. Market Revenue and Volume Forecast, By Product
10.1.9.2. Market Revenue and Volume Forecast, By Research Phase
11.1. Seqens
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Recipharm Venture Fund
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. CordePharma
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Siegfried Holdings AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Lonza Group Ltd
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Boehringer Ingelheim
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Catalent
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. AGC Biologics
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. 3P Biopharmaceuticals
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Adragos Pharma
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample